Impact Report

Together, we're creating a better world for everyone affected by rare kidney disease.

July 2024
—
July 2025


NEPHCURE
25
25 YEARS CLOSER TO A CURE FOR RKD

Table of Contents


NephCure
for Rare Kidney Disease

Letter from Our Team

Dear NephCure Supporters,

This year, more than ever, we have been reminded why NephCure exists. Every story we've heard from a patient, every hand we've shaken at an event, every breakthrough discussed in a meeting room has reinforced the urgency of our mission and the extraordinary impact we can make when we stand together. This report was compiled to celebrate the impact made possible by your support and share why your ongoing commitment is so vital to the future of the rare kidney disease community.

In these pages, you'll see moments that define what it means to be part of NephCure: patients finding answers after years of uncertainty, young advocates using their voices, researchers joining forces across continents to accelerate new treatments, and families discovering hope where there was once only fear. These aren't just programs and initiatives, they are lifelines.

None of this progress happens without you. The NephCure community is made up of generous, compassionate, and determined people, and we are honored to walk this journey by your side. Your support accelerates vital research and brings new treatments to those who need them most. Because of you, patients are greeted with guidance, education, and community. Through your investment, screening and early detection for rare kidney disease is expanding, opening doors to earlier diagnosis and care. As you read through this report, you should see yourself in every milestone. You are the reason people with RKD can dream bigger, move faster, and reach farther. And while there is still much work ahead, we face it with determination and deep gratitude for your continued investment that will make it possible.

From all of us at NephCure, thank you for believing in a future where every rare kidney disease patient receives timely access to care and treatment. Your support is making that future a reality.

With gratitude and hope,

The NephCure Team

Our Impact by the Numbers

Since 2000, Together We've...

Fueled more than **$40MM** in pivotal research projects like NEPTUNE, CureGN, and others to better understand the causes and potential treatments for rare kidney diseases, leading to discoveries like APOL1 and anti-nephrin.

Paved the way for life-changing drug development, leading to **6 FDA-approved treatments** now available to patients.

Ensured patient awareness and education of **60+ clinical drug trials.**

Advanced global projects to support improved care and better treatments for RKD, including the Gateway Initiative in 2018, the creation of ISGD in 2022, the MN Workshop in 2023, the SGLT2i for Pediatrics project in 2023, and SEISMIC and IgAN Alliance in 2025.

Amplified the patient experience throughout the year by completing approximately **25 Voice of the Patient projects annually,** as well as organizing advisory boards and panels to inform clinical trial design, facilitate drug development, and improve clinical care.

Built the largest network of rare kidney disease patients worldwide, reaching more than **40,000 patients and families** each year.

Created the largest annual gathering of RKD patients worldwide, connecting **300+ patients and partners** to help navigate their RKD journey.

Connected patients to over **200 NephCure Specialists,** a network of physician experts in rare glomerular diseases.

Led efforts to introduce the **first and only federal bill** addressing rare kidney disease policy.

Built a **trial matching tool** to connect patients with relevant clinical trials.

Mobilized **430 volunteers** to advocate for rare kidney disease in their communities.

Research and Innovation Advancements

PARASOL Paves the Way for New FSGS Treatments

Focal Segmental Glomerulosclerosis (FSGS) is a serious and rare kidney disease and a leading cause of kidney failure, with no FDA-approved drugs to treat it. For patients, every day without treatment and proper care can bring irreversible kidney damage. The complexity of this disease has long challenged researchers, making it unclear how or when new medicines could reach those who need them most.

That's why NephCure helped launch the Proteinuria and GFR as Clinical Trial Endpoints in Focal Segmental Glomerulosclerosis (PARASOL) Project. PARASOL is a groundbreaking, global effort to break through one of the biggest barriers in rare kidney disease drug development and create pathways for new treatments for FSGS.

PARASOL united researchers, clinicians, regulators, industry partners, and patient advocates from around the world to prove that reducing protein in the urine (proteinuria) can serve as a reliable measure for testing the effectiveness of potential new FSGS treatments. This transformative milestone has unblocked progress in FSGS drug development and means that clinical trials can now be designed smarter, run faster, and bring life-changing therapies to patients sooner.

In just over a year, PARASOL gathered and analyzed data from more than 26 global registries made possible by thousands of patients, held three international scientific workshops, and built global consensus. We accomplished what normally takes many years in record time. PARASOL's impact is already creating positive change: a drug called FILSPARI® (sparsentan) which showed significant reductions in proteinuria in FSGS trials, is now under review at the FDA, with a potential decision date in January. There are also several other potential new FSGS treatments that are using urine protein reduction as their primary trial goal. Because of these monumental efforts, we can offer a new horizon of hope to families who have been waiting too long. The success of PARASOL is proof that when the global community works together with urgency and compassion, we can rewrite what's possible for rare kidney disease. Moving forward, the "PARASOL formula" of rapid, collaborative, multi-stakeholder engagement will serve as a model to accelerate research and treatment development for other rare kidney diseases in urgent need of new therapies.

> **"PARASOL is an incredible demonstration by the international nephrology community that through generosity and multidisciplinary collaboration, we can answer fundamental, practical scientific questions needed to inform clinical trial design in rare disease."**
>
> **DR. LAURA MARIANI**
>
> PARASOL Co-Chair and Associate Professor of Medicine (Nephrology) at the University of Michigan

Creating a SEISMIC Impact for C3G Patients

For patients with Complement 3 glomerulopathy (C3G) and Immune Complex-Mediated Membranoproliferative Glomerulonephritis (IC-MPGN), these ultra rare kidney diseases often carry a near-universal narrative: delayed diagnosis, limited treatments, and lives put on hold. Earlier this year, we were thrilled to see the first-ever drugs to treat these conditions approved by the FDA. However, without a clear path to ensure more accurate diagnoses, to connect patients with these ultra-rare conditions to physician experts, and to improve clinical care guidelines, it was not clear how C3G and IC-MPGN patients could actually benefit from these new treatments.

The SEISMIC Summit (Cross-Stakeholder Summit Addressing C3G and IC-MPGN Diagnosis and Treatment Access) changed that, gathering clinicians, researchers, regulators, patient advocates, and industry leaders from across the globe in Reykjavik, Iceland, to do more than talk; they charted a path toward real change. Held July 17–19, 2025, this invitation-only summit convened close to 100 key stakeholders to tackle the complex barriers that stand between promising new therapies and the patients who urgently need them.

What emerged was more than a meeting; it was progress. Through shared experiences, patient and physician insights, and hard-won data, SEISMIC created actionable consensus and alignment on a clear path forward. Physician and expert working groups are now moving forward to streamline the diagnosis procedure, improve access to expert care through Centers of Excellence, and create clear physician guidelines and insurance approval pathways that will enable patients to access these life-changing treatments.

In Reykjavík, ambition turned into strategy. SEISMIC planted the seeds for progress at a moment when hope must be matched with tangible results. For patients and the physicians, researchers, and other partners invested in their future, it signals a future of continued breakthroughs, together.

> “I want to thank each and every one of you. It is absolutely clear that you all are engaged, and passionate about next steps. Your contributions already inform the formidable base of the SEISMIC change we all feel is coming. Buckle up!”

DR. CARLA NESTER

Professor of Pediatrics and Division Director of Pediatric Nephrology,
University of Iowa

Patient Spotlight

Teleya B.

Diagnosed with FSGS at 14, Teleya did not let her diagnosis define her, and chose to embrace life to the fullest. With her condition stable for two decades, she traveled to over 80 countries.

Sadly, in her 30s, her condition worsened to stage 3B. After COVID severely damaged her kidney function, she began dialysis and later faced an unsuccessful transplant.

“Initially, I was afraid to share my story as a teen because I thought my kidney disease was somehow my fault. It wasn’t until I was much older through a kidney gene panel that I discovered my FSGS was connected to an APOL-1 variant that ran through both sides of my family. After my failed transplant this summer, I really wanted support and to speak with other people with my rare disease,” said Teleya.

Through everything, Teleya has learned that knowledge truly is power. Understanding her disease helped her find peace and strength in her journey. She believes that when patients are educated about their condition, they can face the future with confidence and hope instead of fear.

Launch of the IgAN Alliance

For decades, people living with IgA nephropathy (IgAN) had few options beyond steroids and other harsh immunosuppressive drugs. Too often, these treatments fell short, leaving many patients to face kidney failure, dialysis, or the need for a transplant. Today, thanks to groundbreaking research and innovation, there is new hope. For the first time, FDA-approved therapies can slow the progression of IgAN and help preserve kidney function. Yet these advances are only as powerful as the speed at which they reach the people who need them most. For too many patients, diagnosis still comes too late, and access to new therapies remains full of hurdles.

With your support, NephCure is leading the charge to close this gap. Launched in 2025, the IgAN Alliance is a first-of-its-kind collaboration uniting patients, clinicians, researchers, pharmaceutical industry members, and policy experts to ensure that every patient can access timely, expert care.

In its first year, the Alliance raised national awareness through a patient-finding campaign that reached thousands of families, empowered patients and caregivers with new educational tools, and gathered insights from patient and physician communities to align on the biggest barriers to care.

IgAN Alliance

> **My journey to diagnosis had ups and downs. I did the shuffle of going to the urologists and they said 'we can't help you we don't know what this is' and then I went to the nephrologist and still did not have the answers right away."**

JENNIFER R.
IgA Nephropathy Patient

Launch of the IgAN Alliance Cont.

Now, the Alliance is moving from insight to action—expanding early screening and specialist referrals, equipping physicians and patients with resources for shared decision-making, and addressing insurance and policy barriers to ensure that promising therapies reach patients before irreversible kidney damage occurs.

New treatments can only change lives if patients can access them. The IgAN Alliance is uniquely positioned to shape a future where every IgAN patient receives timely diagnosis, expert care, and access to life-changing therapies. Together, we can ensure innovation reaches those who need it most. Stay informed and connected with the latest IgAN Alliance news and resources at IgANAlliance.org.

Building and Strengthening the Patient Community

Hill Day

On July 23–24, 2025, NephCure hosted its largest-ever *Rare Kidneys on the Hill Day*. With your backing, 78 advocates from 24 states traveled to Washington, D.C., to meet face-to-face with lawmakers and push for lasting change in rare kidney disease care.

This year's focus was the New Era of Preventing End-Stage Kidney Disease Act (H.R.1518) — a bipartisan bill designed to change the trajectory of rare kidney disease.

If passed, the bill will:

- ✓ Establish NIH Centers of Excellence to accelerate kidney disease research
- ✓ Expand early diagnosis through genetic testing
- ✓ Improve care in underserved communities
- ✓ Strengthen training for nephrologists and primary care providers
- ✓ Drive research on treatments to reduce the need for dialysis and transplants

Because of you, our advocates held 116 congressional meetings in just two days, sharing deeply personal experiences of delayed diagnoses, scarce treatment options, and the emotional toll of living with rare kidney disease (RKD).

> **"We need early prevention, we need to prevent people from being in end-stage kidney failure into dialysis and stop spending $141 billion on dialysis and transplant."**
>
> **SHANNON M.**
> Patient Parent

Patient & Youth Summit

On April 3-5, 2025, the NephCure community met under the city lights of Times Square in New York City for our annual Patient and Youth Summit. Both the NephCure Patient and Youth Summits were an uplifting blend of education, compassion, and community building that brought together 268 patients, families, caregivers, and health care allies. Roughly one-third of attendees received scholarships that made their attendance possible, thanks to supporters like you.

This gathering was a powerful reminder that no one fights rare kidney disease alone. Attendees heard from leading experts, researchers, and those personally touched by RKD, gaining actionable insights into disease management, mental well-being, nutrition, and more.

Children and teens who are affected by RKD or have a sibling with RKD also had a dedicated space in the Youth Summit,

a program running alongside the main Patient Summit. This safe and supportive environment gave young participants the opportunity to learn, connect, and feel empowered. For many, it was the first time meeting someone their age with a rare kidney disease. Through interactive activities, they discovered how the kidneys work, gained insights on nutrition and kidney-healthy eating, and explored important conversations around mental health. The Youth Summit provided not only knowledge but also comfort and the confidence to face their journey with strength. The highlight of the event was a trip to the Empire State Building on a double-decker bus. It is safe to say that unforgettable memories were made amongst our youngest kidney warriors this past year in New York City.


NephCure Patient Summit Attendees by Disease Type

> “Get to a NephCure event – it’s life-changing, it changed my life, it will change yours.”

DANIEL H.

Membranous Nephropathy Patient

> “Definitely do come, build connections and relations in this community. They will help you with treatment options, doctor dietary needs, coping mechanisms for your disease and mental health.”
>
> **LAUREN N.**
> Rare Kidney Disease Patient

Breakfast with NephCure

For many attendees, Breakfast with NephCure is more than an educational event, it’s their first touchpoint with NephCure. And for many, it is the first time they’ve met another person living with a rare kidney disease. Our Breakfast with NephCure events are a warm introduction to the rare kidney disease community over the most important meal of the day. They take place in major cities across the U.S. throughout the year so that as many people as possible can attend. So far, this year, we have had 130 attendees attend events in St. Louis, Phoenix, Minneapolis, Tampa, Salt Lake City, and Philadelphia. Patients and caregivers gather to learn from leading specialists, hear the latest updates on research and treatments, and discover resources that help them navigate their condition. Attendees leave not only better informed but also feeling supported, understood, and connected to others who truly share their journey.

Patient Spotlight

Jen M.

Meet Jen, a patient diagnosed with FSGS.

After noticing her ankles were the size of grapefruits, Jen was diagnosed with FSGS at age 17. Maintenance medications sustained her through five semesters of college, after which her mother, Judy, donated her kidney to Jen in 1999.

Seven days later, the donated kidney was determined to be unviable and was removed. This led to six months of hemodialysis and then six months of peritoneal dialysis before Jen received her second kidney from her father, Jim. The transplant came just two weeks after graduating with her Bachelor's degree. Her father's kidney gave her a 6 ½ year hiatus from dialysis. During this time, Jen traveled the world, returned to college to obtain her master's degree in teaching, and became an elementary school teacher. Jen then returned to peritoneal dialysis for about three years while the search for another matching kidney was ongoing.

However, she did not need to search too far or too long, as her Uncle Dave was a match and gave Jen a third kidney in 2008, which has been affectionately named "UDK" (Uncle Dave's Kidney). Although there is recurrence of FSGS in the transplanted kidney, Jen is proudly in partial remission with a baseline creatinine of 1.7.

Teen Takeover Weekend

This weekend-long event was created as a supportive space for teenagers and their families navigating RKD to connect, build confidence, and prepare for the transition from pediatric to adult care.

Becoming a young adult is already a major life adjustment. For teens living with RKD, that transition brings added challenges, including learning to take greater responsibility for their health, understanding treatment options, and developing the confidence to advocate for themselves. Academic success can also require extra support, from knowing how to request accommodations to managing stress and maintaining mental well-being. Just as importantly, teens with rare diseases need community. Living with a rare condition can feel isolating, and having peers who understand makes a meaningful difference.

With guidance from Dr. Sreedhar Mandayam, an adult nephrologist and NephCure Specialist, along with two inspiring young adult mentors—Sean Converse (living with IgA Nephropathy) and Keyaira Sanders (living with Minimal Change Disease)—eleven teens and their families gained valuable insight into what adulthood with RKD can look like and how to approach it with confidence and support.

Instead of lecture-style programming, Teen Takeover offered teens and their caregivers a series of fun, age-appropriate sessions that tackled everything from medication management to identity and independence.

The event's emotional impact was echoed in post-session chats, group messages, and feedback collected throughout the weekend:

> **“This weekend filled my cup. So grateful.”**

> **“My soul needed this.”**

> **“She didn't realize how much she needed to form these connections.”**

> **“I feel so grateful for the information I received but I am most grateful that I made real connections.”**

Parents expressed appreciation for the space to connect with one another and learn directly from young adults who had already walked the path their children are on. Teens found relief in not having to explain themselves, they were simply understood.

Teen Takeover Weekend showed just how meaningful it is to give teens and their families a space that's built specifically for them. From shared stories to honest conversations, the weekend created a sense of connection and understanding that many didn't realize they needed.

Awareness Days

We know that awareness ignites action. Over the past year, NephCure has supported Rare Kidney Disease Awareness Days for IgAN, C3G, APOL1, and FSGS. These days create meaningful moments for patients, families, clinicians, and partners as they unite around a shared cause.

Each campaign harnesses the power of social media and digital advertising to educate people about rare kidney disease, encourage them to share their personal story, and empower our community. We launched individual hybrid campaigns (both digital and traditional), which in total reached well over half a million users on social media, added 1500+ members to our community, and attracted 300+ webinar registrations.

Looking ahead, we are committed to expanding this initiative to recognize even more rare kidney conditions. Awareness days prove the extraordinary power of our community's collective voice: in just 24 hours, our community comes together to amplify stories, highlight advances, and rally support for those living with rare kidney disease. We want to ensure that every person living with a rare kidney disease not only understands but truly feels they are not alone.

NephCure Specialists

Behind every breakthrough in rare kidney disease is a clinician who listens, who cares, and who refuses to give up on their patients. That is the spirit of the NephCure Specialist Program. Since its founding in 2018, this program has grown into a trusted network of more than 200 dedicated nephrologists, including 131 adult specialists and 70 pediatric specialists, who provide hope for families navigating rare kidney diseases.

These physicians are not only leaders in clinical care, but also champions of research, education, and advocacy. Their dedication ensures that patients have access to accurate diagnoses, cutting-edge treatments, and the support they need to navigate complex health challenges.

Through the program, Specialists:

- ✓ Join a national elite network of care partners that help patients find expert care and second opinions
- ✓ Receive patient referrals
- ✓ Gain access to educational resources
- ✓ Are able to attend NephCure events where they are given speaking opportunities and are able to connect with our community
- ✓ Contribute to groundbreaking scientific workshops and research initiatives
- ✓ Have the opportunity to join NephCure's Physician Advisory Boards
- ✓ Advocate for policies that advance rare kidney disease research and treatment

NephCure Specialists are the ones patients turn to when answers are hard to find. They bring clarity to confusing diagnoses, open doors to cutting-edge treatments, and stand beside families through the uncertainty of rare disease journeys. This network is proof that when clinicians, patients, and advocates work together, the impact is profound.

> **"The research funding I found out about from NephCure was vital to my work on development of a new class of drugs, podocyte endoplasmicreticulum calcium stabilizers, to treat nephrotic syndrome. In the academic community, it's critical to receive timely notification of these opportunities and be connected with the funding decision makers."**

DR. MAGGIE CHEN

Associate Professor of Medicine,
Washington University School of Medicine

Screening and APOL1 Awareness

Rare Kidney Disease Screenings

NephCure's Rare Kidney Disease Screening Campaign is a nationwide initiative designed to promote early intervention by providing free testing, delivering vital education, and connecting individuals to treatments and care.

As part of this campaign, this spring, NephCure partnered with Enon Tabernacle Baptist Church to support their *"Men Know Your Numbers"* event. This powerful day was dedicated to empowering an underserved and at-risk community to take charge of their health. The church transformed its sanctuary into a full-service wellness clinic, offering free screenings for blood pressure, cholesterol, prostate cancer, mental health, and more.

Because of NephCure, participants also had access to on-site urine screenings for kidney disease and groundbreaking genetic testing for APOL1-related kidney disease, which disproportionately impacts African American communities.

In the fall, we proudly participated in the 54th Annual Legislative Conference of the Congressional Black Caucus Foundation, held in Washington, D.C., where we also brought our screening tests, resources and support.

> **Collaborations work! NephCure's mission aligns with our commitment to be proactive and preventative in our approach to health and wellness."**
>
> **REV. LEROY MILES**
> Enon Tabernacle Baptist Church,
> NephCure Board Member

Health Equity Conference

Titled *"From Awareness to Action: Health Equity and Kidney Care in Black America,"* the event was a landmark gathering that addressed the urgent disparities impacting Black communities. A total of 120 patients, clinicians, policymakers, and community leaders came together not only to share knowledge but also to drive meaningful change.

To put the challenges facing the African American community into perspective:

- African Americans are 5 times more likely to get FSGS in comparison with the general population.
- African Americans make up 13% of the US population but account for nearly 35% of people with kidney failure in the US.
- 1 in 8 African Americans is at risk of a genetic form of kidney disease (caused by the APOL1 gene mutations).
- Rare APOL1 kidney disease is particularly aggressive. Approximately 40% of African Americans on dialysis have kidney failure caused by APOL1.

Through powerful workshops, inspiring speakers, and honest conversations, the conference illuminated the disproportionate impact of rare kidney diseases in Black communities and equipped attendees with tools to create more just, accessible, and compassionate care systems.

The conference was a powerful reminder that when communities unite for equity, they also create space for hope, healing, and progress.

Patient Spotlight

Anthony S.

Five-year-old Anthony has been battling minimal change disease (MCD) since he was 2. Diagnosed after a bizarre swelling episode post-COVID, he's become the "head-scratcher" for doctors due to his atypical symptoms, minimal swelling, and little to no treatment response.

"Anthony continues to spill 300+ protein daily and somehow stays strong. Despite all this, we've refused to let the disease control his life. He's active, goes to school, and enjoys life just like any other kid. Whether it's eating at parties or playing sports, we do our best to let him be himself.

Our hope lies in new research and treatments. We will continue to fight this disease with love, hope, and determination, and pray that the challenges Anthony faces will soon be answers for the warriors of the future," said Anthony's mom, Jennifer.

"As a Nephcure Specialist, I had the opportunity to participate in an incredibly successful family event this past spring in NYC, The NephCure Youth Summit. Many of our families attended and one of them connected with other families and the boy with glomerular disease and CKD attended our kidney camp program at Frost Valley YMCA in July for the first time, and here is a quote from the mother:

> *"My child had an amazing experience at the camp. He enjoyed every minute of it. He became a new person. More confident, more independent, more energetic and so proud of himself for coming out of his comfort zone. Please give our thanks to all the staff."*

DR. FREDERICK KASKEL

Vice Chairman of Pediatrics and Director
of Pediatric Nephrology at the Albert
Einstein College of Medicine

Mission and Looking Ahead

NephCure: Driving a New Era for Rare Kidney Disease

Our Journey Together

Twenty-five years ago, families facing rare, protein-spilling kidney diseases (RKD) had little hope. There was limited scientific understanding, no FDA-approved treatments, and virtually no drugs in development. Patients lived with uncertainty and fear of what the future would hold.

Thanks to your partnership, the story looks very different today. Together, we've helped make six FDA-approved therapies possible, fueled more than 60 clinical trials, and built a thriving community of over 40,000 families who have found knowledge, hope, and connection through NephCure.

Because of you, progress for RKD patients is no longer a dream—it is a reality. And yet, our vision remains larger still: a world where every person with RKD has access to the best treatments and, one day, a cure.

A New Mission for a New Era

With so much progress achieved, we recognize the next challenge: ensuring that every patient can benefit from these innovations in care and treatment. FDA approval is not the finish line—it's the starting line. Too many families still face barriers: late diagnoses, difficulty finding expert physicians, and inequities that delay or block access to care.

That's why, in 2026, we are introducing a **new mission statement**—one that reflects both how far we've come and where we must go next:

Our Mission:

To ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible.

This new mission builds on the progress you've helped us achieve and points us toward the future: not just advancing treatments, but in ensuring patients can reach them.

And at the heart of this mission is a simple promise: that every patient who connects with NephCure will feel supported, informed, and ready to take the next step toward better care and a brighter future.

How We Make an Impact

NephCure is uniquely positioned to create change because we work at many levels. We bring together researchers, clinicians, industry leaders, and policymakers to set priorities and raise the standard of care. At the same time, we walk beside families—providing navigation, education, advocacy, and community.

This approach ensures that progress in science becomes progress in patients' lives. It comes to life through four guiding commitments:

- ✓ **Optimizing outcomes** through earlier diagnoses and faster connections to expert care.
- ✓ **Empowering patients** with knowledge, tools, and support to navigate the healthcare system.
- ✓ **Amplifying patient voices** so lived experiences shape research, policy, and care.
- ✓ **Fostering community and equity** by cultivating a trusted home for all who are affected by RKD.

Why Your Support Matters

- The years ahead will be measured not only by the approval of new treatments, but also by the lives transformed because patients are able to access those treatments. No family should have to wait years for answers. No patient should struggle to find an expert who understands their disease. And no child should lose precious time because the right treatment was out of reach.

With your continued support, NephCure will make this vision real—ensuring that patients are diagnosed and treated earlier, that families can find expert care when they need it most, and that access to life-changing therapies is equitable, timely, and affordable for all.

Together, we are not just advancing science—we are changing lives and building a future filled with hope, equity, and possibility for every person living with rare kidney disease.

Ways to Connect and Give

Ways to Give & Support:

- **Donate online**
- **Fundraise for NephCure**
- **Become a CureMaker**
- **Join our matching gift program**

- **For inquiries regarding corporate partnerships, please contact Britta Dornan at BDornan@NephCure.org**
- **For information about major giving opportunities, please contact Susan Brisendine at Susan@NephCure.org**
- **For all other inquiries, contact us at Events@NephCure.org**


FABHALTA
PATH
FOR YO IgAN
44%
NEPHCURE
2025
PATIENT
SUMMIT
YOUR IgAN JOURNEY
44% vs 9%
NOVARTIS

NephCure
for Rare
Kidney
Disease

Stay connected!

Follow us on social media and visit our website for more.

» NephCure.org «

Find us on social @NephCure